Surgery for cholangiocarcinoma
Authors:
Martin Oliverius 1; Lukáš Havlůj 1; Jan Hajer 2; Renata Soumarová 3; Jan Hrudka 4; Robert Gürlich 1
Authors‘ workplace:
Chirurgická klinika 3. LF UK a FN Královské Vinohrady, Praha
1; 2. interní klinika 3. LF UK a FN Královské Vinohrady, Praha
2; Radioterapeutická a onkologická klinika 3. LF UK a FN Královské Vinohrady, Praha
3; Ústav patologie 3. LF UK a FN Královské Vinohrady, Praha
4
Published in:
Čas. Lék. čes. 2019; 158: 73-77
Category:
Review Article
Overview
Cholangiocarcinoma represents the second most common primary liver malignancy. Despite it comprises only 3 % of all gastrointestinal malignancies, its incidence has been increasing recently. Cholangiocarcinomas are hepatobiliary cancers with features of cholangiocyte differentiation and from clinical point of view they are classified anatomically as intrahepatic or extrahepatic form. The only curative treatment with aim of long term and disease-free survival is surgery – liver resection or liver transplantation. Current progress in perioperative treatment and increased surgical skills has changed old treatment algorithms and widen number of patients suitable for curative treatment. On the other hand, surgical intervention is connected with not negligible morbidity and mortality. A rigorous knowledge of the disease extent and all prognostic factors is main condition for proper treatment decision.
Keywords:
cholangiocellular carcinoma – liver resection
Sources
1. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54(1): 173–184.
2. De Oliviera ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245(5): 755–762.
3. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009; 136(4): 1134–1144.
4. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 2013; 11(1): 13–21.e1.
5. Nakanuma Y, Sato Y, Harakada K et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010 27; 2(12): 419–427.
6. Komuta M, Govaere O, Vandecaveye V et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 2012; 55(6): 1876–1888.
7. Sasaki K, Margonis GA, Andreatos N et al. Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. HPB (Oxford) 2018; 20(10): 956–965.
8. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48(4): 1106–1117.
9. Sinakos E, Saenger AK, Keach J et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011; 9(5): 434–439.e1.
10. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004; 24(2): 139–154.
11. Zhang YF, Chakedis J, Bagante F et al. Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. Br J Surg 2018; 105(7): 857–866.
12. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014; 149(6): 565–574.
13. Amini N, Ejaz A, Spolverato G et al. Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol 2014; 110(2): 163–170.
14. Spolverato G, Kim Y, Alexandrescu S et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 2016; 23(1): 235–243.
15. Zhang XF, Beal EW, Bagante F et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg 2018; 105(7): 848–856.
16. Hyder O, Hatzaras I, Sotiropoulos GC et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013; 153(6): 811–818.
17. Sulpice L, Rayar M, Boucher E et al. Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg 2012; 99(12): 1711–1717.
18. Zamora-Valdes D, Heimbach JK. Liver transplant for cholangiocarcinoma. Gastroenterol Clin North Am 2018; 47(2): 267–280.
19. Lunsford KE, Javle M, Heyne K et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 2018; 3(5): 337–348.
20. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975; 140(2): 170–178.
21. Uenishi T, Hirohashi K, Kubo S et al. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg 2001; 25(7): 865–869.
22. Yamaguchi K, Chijiiwa K, Saiki S et al. Carcinoma of the extrahepatic bile duct: mode of spread and its prognostic implications. Hepatogastroenterology 1997; 44(17): 1256–1261.
23. Hanazaki K, Kajikawa S, Shimozawa N et al. Hepatic resection for hepatocellular carcinoma in diameter of > or = 10 cm. Hepatogastroenterology 2002; 49(44): 518–523.
24. Suzuki S, Sakaguchi T, Yokoi Y et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg 2002; 26(6): 687–693.
25. Fukami Y, Ebata T, Tokoyama Y et al. Diagnostic ability of MDCT to assess right hepatic artery invasion by perihilar cholangiocarcinoma with left-sided predominance. J Hepatobiliary Pancreat Sci 2012; 19(2): 179–186.
26. Senda Y, Nishio H, Oda K et al. Value of multidetector row CT in the assessment of longitudinal extension of cholangiocarcinoma: correlation between MDCT and microscopic findings. World J Surg 2009; 33(7): 1459–1467.
27. Ruys AT, Van Beem BE, Engelbrecht MR et al. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol 2012; 85(1017): 1255–1262.
28. Chari ST, Takahashi N, Levy MJ et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7(10): 1097–1103.
29. Kawakami H, Kondo S, Kuwatani M et al. Preoperative biliary drainage for hilar cholangiocarcinoma: which stent should be selected? J Hepatobiliary Pancreat Sci 2011; 18(5): 630–635.
30. Ribero D, Zimmitti G, Aloia TA et al. Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma. J Am Coll Surg 2016; 223(1): 87–97.
31. Nagino M, Ebata T, Yokoyama Y et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 2013; 258(1): 129–140.
32. Nagino M, Kamiya J, Nishio H et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 2006; 243(3): 364–372.
33. Hong YK, Choi SB, Lee KH et al. The efficacy of portal vein embolization prior to right extended hemihepatectomy for hilar cholangiocellular carcinoma: a retrospective cohort study. Eur J Surg Oncol 2011; 37(3): 237–244.
34. Kondo S, Hirano S, Ambo Y et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg 2004; 240(1): 95–101.
35. Belina F. Hilar cholangiocarcinoma (Klatskin tumor) – current treatment options. Rozhledy v chirurgii 2013; 92(1): 4–15.
36. De Oliviera ML, Schulick RD, Nimura Y et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011; 53(4): 1363–1371.
37. Amin MB, Edge S, Greene F et al. AJCC Cancer Staging Manual (8th ed.). Springer, Berlín, 2016.
38. Ebata T, Mizuno T, Yokoyama Y et al. Surgical resection for Bismuth type IV perihilar cholangiocarcinoma. Br J Surg 2018; 105(7): 829–838.
39. Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242(3): 451–461.
40. Darwish Murad S, Kim WR et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143(1): 88–98.e3.
41. Croome KP, Rosen CB, Heimbach JK, Nagorney DM. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma? J Am Coll Surg 2015; 221(1): 130–139.
42. Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: a systematic review and meta-analysis of prognostic factors. Asian J Surg 2017; 40(2): 129–138.
43. Wellner UF, Shen Y, Keck T et al. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today 2017; 47(3): 271–279.
44. Maeta T, Ebata T, Hayashi E et al. Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma. Br J Surg 2017; 104(11): 1549–1557.
45. Mansour JC, Aloia TA, Crane CH et al. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015; 17(8): 691–699.
46. Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36(3): 321–327.
47. Shin HR, Lee CU, Park HJ et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996; 25(5): 933–940.
48. Nathan H, Pawlik TM, Wolfgang CL et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 2007; 11(11): 1488–1497.
49. Vilchez V, Shah MB, Daily MF et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB (Oxford) 2016; 18(1): 29–34.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
2019 Issue 2
Most read in this issue
- Surgery for cholangiocarcinoma
- Pathology of cholangiocellular carcinoma
- Artificial intelligence and modern information and communication technologies entering medicine
- Epidemiology of gallbladder and bile duct malignancies in the Czech Republic